a bit of history, page-2

Resonance Health has had a strong start to 2011 with some significant developments in the growth of FerriScan and the development of pipeline products which provide significant revenue opportunity for the Company.

FerriScan sales volumes grew 18% in the first quarter.
11 new FerriScan imaging centres established in the last 4 months.
New distributors appointed to market FerriScan in the Middle East.
Next phase of development of the Company's liver fibrosis test commenced with international pharma company.
Exclusive international licence signed for imaging diagnostic technology for assessing fibrosis and amyloidosis.
MRI-based diagnostic tool for cardiac iron submitted to FDA for regulatory approval.
FDA submission being prepared for liver fat diagnostic device to address the very large non-alcoholic fatty liver disease market.